MNV
Market News Video
MNV MNV 10 Stocks Crossing Below Book Value
MNV
MNV
MNV
MNV
MNV
MNV
MNV
Free Dividend Report - Top Ranked Stocks

Featured MNV Articles:

Pfizer Now #19 Largest Company, Surpassing Visa
Thursday, February 16, 4:37 PM ET, by Market News Video Staff

In the latest look at the underlying components of the S&P 500 ordered by largest ...

The Math Shows XLV Can Go To $81
Friday, February 17, 9:38 AM ET, by Market News Video Staff

Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, ...

XLV, PFE, MRK, LLY: ETF Outflow Alert
Tuesday, February 21, 10:57 AM ET, by Market News Video Staff

Symbols mentioned in this story: XLV, PFE, MRK, LLY Exchange traded funds (ETFs) trade just ...

Noteworthy ETF Outflows: IHI, ABT, TMO, DHR
Wednesday, February 22, 10:58 AM ET, by Market News Video Staff

Symbols mentioned in this story: IHI, ABT, TMO, DHR Exchange traded funds (ETFs) trade just ...

Notable Wednesday Option Activity: DOW, BMY, GOOG
Wednesday, February 22, 1:25 PM ET, by Market News Video Staff

Looking at options trading activity among components of the S&P 500 index, there is noteworthy ...

  More articles:  1 2 3 4 5 6 7 next »

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer

By Market News Video Staff, Monday, August 29, 8:47 AM ET
Play Video: The Importance of ETFs


If the video does not load after a few moments, Upgrade to the Latest Flash Player.

Bristol-Myers Squibb (NYSE:BMY) and Pfizer (NYSE:PFE) announced over the weekend positive results in a Phase 3 trial that compared Elquis to warfarin for the prevention of stroke or systemic embolism in patients with atrial fibrillation and at least one risk factor for stroke.

The companies said the drug showed Elquis significantly reduced the risk of stroke or systemic embolism by 21%, major bleeding by 31%, and mortality by 11%. Separately, Pfizer said that the Food and Drug Administration has approved Xalkori capsules, which the company calls the first-ever drug targeting anaplastic lymphoma kinase, or ALK, for the treatment of locally advanced or metastatic non-small cell lung cancer that is ALK-positive.

Pfizer noted that lung cancer is responsible for more deaths each years worldwide than any other type of cancer, and the drug offers a new treatment option for a subset of patients with the disease.

The FDA gave the drug accelerated approval, and Pfizer is conducting post-marketing clinical trials to further evaluate its clinical benefit. Pfizer partnered with Abbott Laboratories’ (NYSE:ABT) Molecular business on a diagnostic test for ALK, which was approved simultaneously with the drug. Xalkori is available immediately through some pharmacies.


Top Six Most Viewed Stories This Week @ Market News Video:

This Article's Word Cloud:   Abbott   Administration   Elquis   Food   Molecular   Myers   NYSE   Pfizer   Xalkori   advanced   approved   atrial   benefit   business   cancer   capsules   clinical   compared   diagnostic   disease   drug   each   embolism   evaluate   further   least   lung   lymphoma   marketing   mortality   offers   over   partnered   patients   pharmacies   positive   risk   said   small   some   stroke   subset   systemic   targeting   that   treatment   which   with   worldwide   years
MNV
MNV
About Us - Advertise - Contact Us - Embedding Videos - Licensing Videos - Partners - mRSS / RSS Feed - Terms of Use - Privacy Policy - Video Widget
MNV
Home  |  Analyst News  Dividend Report  ETFs  Insider Report  Large Caps  Market Movers  Week Ahead Report  Weekly Market Wrap
MNV
MNV MNV Stock Message Boards Stock Market Definitions
MNV

Bristol-Myers, Pfizer Announce Positive Results; An FDA Approval for Pfizer | Market News Video | Copyright © 2008 - 2017, All Rights Reserved

Any ideas and opinions presented in all Market News Video clips are for informational and educational purposes only, and do not reflect the opinions of BNK Invest, Inc. or any of its affiliates, subsidiaries or partners. In no way should any content contained herein be interpreted to represent trading or investment advice. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. Read Full Disclaimer.